BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38448996)

  • 1. Prediction model for EBV infection following HLA haploidentical matched hematopoietic stem cell transplantation.
    Cao XH; Fan ZY; Chang YJ; Xu LP; Zhang XH; Huang XJ; Zhao XY
    J Transl Med; 2024 Mar; 22(1):244. PubMed ID: 38448996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
    Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation.
    Zhou L; Lu DP
    Virol J; 2019 Feb; 16(1):19. PubMed ID: 30736814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early T-cell reconstitution predicts risk of EBV reactivation after allogeneic hematopoietic stem cell transplantation.
    Huang J; Pan Z; Wang L; Zhang Z; Huang J; Jiang C; Cai G; Yin T
    Clin Exp Med; 2024 Jan; 24(1):22. PubMed ID: 38280072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevalence of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
    Han TT; Xu LP; Liu DH; Liu KY; Zhang XH; Chen H; Chen YH; Han W; Wang FR; Wang Y; Wang JZ; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):651-4. PubMed ID: 23978013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
    Niu YY; Dong YJ; Yin Y; Xu WL; Liang ZY; Wang Q; Li Y; Liu W; Ou JP; Ren HY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):904-910. PubMed ID: 35045651
    [No Abstract]   [Full Text] [Related]  

  • 7. [Dynamic monitoring of plasma Epstein-Barr Virus DNA load can predict the occurrence of lymphoproliferative disorders after haploidentical hematopoietic stem cell transplantation].
    Chen J; Sun YQ; Xu LP; Zhang XH; Liu KY; Mo XD; Cheng YF; Huang XJ; Wang Y
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):284-288. PubMed ID: 37356996
    [No Abstract]   [Full Text] [Related]  

  • 8. [Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation].
    Lu Y; Wu T; Cao XY; Wang JB; Sun Y; Zhao YL; DA WM; Ji SQ; Tong CR; Lu DP
    Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):383-7. PubMed ID: 21624219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of plasma and peripheral blood mononuclear cells Epstein-Barr Virus DNA dynamics on prognosis of allogeneic stem cell transplantation.
    Zhou X; Lu X; He J; Xu Z; Li Q; Ye P; Zhong Z; Shi W; Yan H; You Y; Hu Y; Wang H
    Front Cell Infect Microbiol; 2022; 12():980113. PubMed ID: 36189344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
    Bao X; Zhu Q; Qiu H; Chen F; Xue S; Ma X; Sun A; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):138-43. PubMed ID: 27014984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.
    Kobayashi S; Sano H; Mochizuki K; Ohara Y; Takahashi N; Ohto H; Kikuta A
    Pediatr Int; 2017 Sep; 59(9):973-978. PubMed ID: 28581032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical risk factors and prognostic model for idiopathic inflammatory demyelinating diseases after haploidentical hematopoietic stem cell transplantation in patients with hematological malignancies.
    Deng RX; Wu YJ; Xu LP; Liu KY; Huang XJ; Zhang XH
    Am J Hematol; 2021 Nov; 96(11):1407-1419. PubMed ID: 34350623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation.
    Xuan L; Jiang X; Sun J; Zhang Y; Huang F; Fan Z; Guo X; Dai M; Liu C; Yu G; Zhang X; Wu M; Huang X; Liu Q
    Transplantation; 2013 Sep; 96(6):560-6. PubMed ID: 23842192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr Virus Reactivation After Paediatric Haematopoietic Stem Cell Transplantation: Risk Factors and Sensitivity Analysis of Mathematical Model.
    Kania SP; Silva JMF; Charles OJ; Booth J; Cheung SYA; Yates JWT; Worth A; Breuer J; Klein N; Amrolia PJ; Veys P; Standing JF
    Front Immunol; 2022; 13():903063. PubMed ID: 35903096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
    Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
    Zhu CY; Zhao SS; Wang XK; Wang L; Wang FY; Fang S; Liu ZX; Guan LX; Liu YC; Ding Y; Dou LP; Wang LL; Gao CJ
    Ann Transplant; 2019 Apr; 24():175-184. PubMed ID: 30940797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience.
    Zhou L; Gao ZY; Lu DP
    Ann Hematol; 2020 Jun; 99(6):1389-1400. PubMed ID: 32291495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.
    Balaguer-Rosello A; Piñana JL; Bataller L; Montoro J; Romero S; Navarro I; Lorenzo I; Andreu R; Guerreiro M; Aguilar C; Gorriz D; Dominguez L; de la Puerta R; Gómez I; Solves P; Jarque I; Sanz MÁ; Sanz G; Sanz J
    Transplant Cell Ther; 2021 Mar; 27(3):261.e1-261.e7. PubMed ID: 33781531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.